Phase II multicenter evaluation of prolonged murine monoclonal antibody 17-1a therapy in pancreatic carcinoma

Louis M. Weiner, Elizabeth Harvey, Kristin Padavic-Shaller, James K V Willson, Christine Walsh, Frank LaCreta, M. B. Khazaeli, John M. Kirkwood, Daniel G. Haller

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Twenty-eight patients with unresectable, measurable pancreatic carcinoma and Eastern Oncology Cooperative Group (ECOG) performance status of 0 or 1 were treated with the murine monoclonal antibody 17-1 A, planning to administer 500 mg i.v. three times weekly for 8 weeks. Treatment was well tolerated, with an 18% incidence (five patients) of hypersensitivity reactions. All hypersensitivity episodes occurred in the first 3 weeks of therapy and required treatment discontinuation. Six patients required early discontinuation of therapy due to symptomatic progressive disease and one patient was removed from the study due to a protocol violation. Sixteen patients received the full course of 12 g of antibody. One patient has exhibited a durable partial response. Antibody pharmacokinetics were determined in five patients. In four patients peak 17-1A levels averaged 100 fig/ml with mean harmonic uh of 16.8 h in a one-compartment model. Neither pretreatment nor posttreatment levels of circulating 17-1A changed significantly during the 8 weeks of treatment, This study demonstrates the feasibility and acceptable toxicity of repetitive dosing with an unconjugated murine monoclonal antibody. The lack of efficacy of treatment suggests that factors other than prolonged exposure of tumor and cytotoxic effector cells to murine antibody are required for successful antibody therapy of pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)110-116
Number of pages7
JournalJournal of Immunotherapy
Volume13
Issue number2
StatePublished - 1993

Fingerprint

Antibodies
Therapeutics
Hypersensitivity
Monoclonal Antibodies
Ficus
Edrecolomab
Pancreatic Carcinoma
Feasibility Studies
Secondary Prevention
Pancreatic Neoplasms
Pharmacokinetics
Incidence
Neoplasms

Keywords

  • Monoclonal antibodies
  • Pancreatic cancer
  • Pharmacokinetics

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Immunology and Allergy
  • Pharmacology

Cite this

Weiner, L. M., Harvey, E., Padavic-Shaller, K., Willson, J. K. V., Walsh, C., LaCreta, F., ... Haller, D. G. (1993). Phase II multicenter evaluation of prolonged murine monoclonal antibody 17-1a therapy in pancreatic carcinoma. Journal of Immunotherapy, 13(2), 110-116.

Phase II multicenter evaluation of prolonged murine monoclonal antibody 17-1a therapy in pancreatic carcinoma. / Weiner, Louis M.; Harvey, Elizabeth; Padavic-Shaller, Kristin; Willson, James K V; Walsh, Christine; LaCreta, Frank; Khazaeli, M. B.; Kirkwood, John M.; Haller, Daniel G.

In: Journal of Immunotherapy, Vol. 13, No. 2, 1993, p. 110-116.

Research output: Contribution to journalArticle

Weiner, LM, Harvey, E, Padavic-Shaller, K, Willson, JKV, Walsh, C, LaCreta, F, Khazaeli, MB, Kirkwood, JM & Haller, DG 1993, 'Phase II multicenter evaluation of prolonged murine monoclonal antibody 17-1a therapy in pancreatic carcinoma', Journal of Immunotherapy, vol. 13, no. 2, pp. 110-116.
Weiner LM, Harvey E, Padavic-Shaller K, Willson JKV, Walsh C, LaCreta F et al. Phase II multicenter evaluation of prolonged murine monoclonal antibody 17-1a therapy in pancreatic carcinoma. Journal of Immunotherapy. 1993;13(2):110-116.
Weiner, Louis M. ; Harvey, Elizabeth ; Padavic-Shaller, Kristin ; Willson, James K V ; Walsh, Christine ; LaCreta, Frank ; Khazaeli, M. B. ; Kirkwood, John M. ; Haller, Daniel G. / Phase II multicenter evaluation of prolonged murine monoclonal antibody 17-1a therapy in pancreatic carcinoma. In: Journal of Immunotherapy. 1993 ; Vol. 13, No. 2. pp. 110-116.
@article{4e3ba30ca7e141d59469498316e6f58c,
title = "Phase II multicenter evaluation of prolonged murine monoclonal antibody 17-1a therapy in pancreatic carcinoma",
abstract = "Twenty-eight patients with unresectable, measurable pancreatic carcinoma and Eastern Oncology Cooperative Group (ECOG) performance status of 0 or 1 were treated with the murine monoclonal antibody 17-1 A, planning to administer 500 mg i.v. three times weekly for 8 weeks. Treatment was well tolerated, with an 18{\%} incidence (five patients) of hypersensitivity reactions. All hypersensitivity episodes occurred in the first 3 weeks of therapy and required treatment discontinuation. Six patients required early discontinuation of therapy due to symptomatic progressive disease and one patient was removed from the study due to a protocol violation. Sixteen patients received the full course of 12 g of antibody. One patient has exhibited a durable partial response. Antibody pharmacokinetics were determined in five patients. In four patients peak 17-1A levels averaged 100 fig/ml with mean harmonic uh of 16.8 h in a one-compartment model. Neither pretreatment nor posttreatment levels of circulating 17-1A changed significantly during the 8 weeks of treatment, This study demonstrates the feasibility and acceptable toxicity of repetitive dosing with an unconjugated murine monoclonal antibody. The lack of efficacy of treatment suggests that factors other than prolonged exposure of tumor and cytotoxic effector cells to murine antibody are required for successful antibody therapy of pancreatic cancer.",
keywords = "Monoclonal antibodies, Pancreatic cancer, Pharmacokinetics",
author = "Weiner, {Louis M.} and Elizabeth Harvey and Kristin Padavic-Shaller and Willson, {James K V} and Christine Walsh and Frank LaCreta and Khazaeli, {M. B.} and Kirkwood, {John M.} and Haller, {Daniel G.}",
year = "1993",
language = "English (US)",
volume = "13",
pages = "110--116",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Phase II multicenter evaluation of prolonged murine monoclonal antibody 17-1a therapy in pancreatic carcinoma

AU - Weiner, Louis M.

AU - Harvey, Elizabeth

AU - Padavic-Shaller, Kristin

AU - Willson, James K V

AU - Walsh, Christine

AU - LaCreta, Frank

AU - Khazaeli, M. B.

AU - Kirkwood, John M.

AU - Haller, Daniel G.

PY - 1993

Y1 - 1993

N2 - Twenty-eight patients with unresectable, measurable pancreatic carcinoma and Eastern Oncology Cooperative Group (ECOG) performance status of 0 or 1 were treated with the murine monoclonal antibody 17-1 A, planning to administer 500 mg i.v. three times weekly for 8 weeks. Treatment was well tolerated, with an 18% incidence (five patients) of hypersensitivity reactions. All hypersensitivity episodes occurred in the first 3 weeks of therapy and required treatment discontinuation. Six patients required early discontinuation of therapy due to symptomatic progressive disease and one patient was removed from the study due to a protocol violation. Sixteen patients received the full course of 12 g of antibody. One patient has exhibited a durable partial response. Antibody pharmacokinetics were determined in five patients. In four patients peak 17-1A levels averaged 100 fig/ml with mean harmonic uh of 16.8 h in a one-compartment model. Neither pretreatment nor posttreatment levels of circulating 17-1A changed significantly during the 8 weeks of treatment, This study demonstrates the feasibility and acceptable toxicity of repetitive dosing with an unconjugated murine monoclonal antibody. The lack of efficacy of treatment suggests that factors other than prolonged exposure of tumor and cytotoxic effector cells to murine antibody are required for successful antibody therapy of pancreatic cancer.

AB - Twenty-eight patients with unresectable, measurable pancreatic carcinoma and Eastern Oncology Cooperative Group (ECOG) performance status of 0 or 1 were treated with the murine monoclonal antibody 17-1 A, planning to administer 500 mg i.v. three times weekly for 8 weeks. Treatment was well tolerated, with an 18% incidence (five patients) of hypersensitivity reactions. All hypersensitivity episodes occurred in the first 3 weeks of therapy and required treatment discontinuation. Six patients required early discontinuation of therapy due to symptomatic progressive disease and one patient was removed from the study due to a protocol violation. Sixteen patients received the full course of 12 g of antibody. One patient has exhibited a durable partial response. Antibody pharmacokinetics were determined in five patients. In four patients peak 17-1A levels averaged 100 fig/ml with mean harmonic uh of 16.8 h in a one-compartment model. Neither pretreatment nor posttreatment levels of circulating 17-1A changed significantly during the 8 weeks of treatment, This study demonstrates the feasibility and acceptable toxicity of repetitive dosing with an unconjugated murine monoclonal antibody. The lack of efficacy of treatment suggests that factors other than prolonged exposure of tumor and cytotoxic effector cells to murine antibody are required for successful antibody therapy of pancreatic cancer.

KW - Monoclonal antibodies

KW - Pancreatic cancer

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0027515945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027515945&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 110

EP - 116

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 2

ER -